A bend in the river for cancer genomics
People can be forgiven for thinking that the messages coming out of the American Association for Cancer Research annual meeting in Chicago this week seem to conflict. Finishing up today, the meeting hosted just shy of 17,000 scientists, exhibitors and guests and had several talks expounding the dizzying pace of genome technologies being applied to cancer diagnosis and treatment. At the same time, some speakers warned of the challenges inherent in doing cancer ‘omics.’ … Read more
Genentech, 23andMe to study genetic response to breast cancer drug
Personal genomics company 23andMe and biotechnology firm Genentech are recruiting breast cancer patients to study genetic predictors of how well they respond to the drug Avastin. Read more